SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Therapeutics to Participate in Jefferies 2018 London Healthcare 
Conference 
 
   Oxford, UK, and Cambridge, MA, US, 7 November 2018 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism 
antibiotic innovation, announces that management will conduct one-on-one 
meetings at the Jefferies 2018 London Healthcare Conference, taking 
place 14-15 November 2018 in London, UK. There will be no podium 
presentation. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients, and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for C. 
difficile infection and gonorrhoea and are using our proprietary Discuva 
Platform to expand our pipeline. For more information, visit 
www.summitplc.com and follow us on Twitter @summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK 
 office)                                Tel:                  44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery 
 (US office)                                                     +1 617 225 4455 
 
Cairn Financial Advisers LLP 
 (Nominated Adviser)                    Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)               Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Panmure Gordon (Joint Broker)           Tel:                 +44 (0)20 7886 2500 
Freddy Crossley, Corporate Finance 
 James Stearns, Corporate Broking 
 
MSL Group (US)                          Tel:                     +1 781 684 6557 
                                                      mailto:summit@mslgroup.com 
Jon Siegal                                                   summit@mslgroup.com 
                                               --------------------------------- 
 
Consilium Strategic Communications 
 (UK)                                   Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Jessica Hodgson            mailto:summit@consilium-comms.com 
 /                                              summit@consilium-comms.com 
                                               --------------------------------- 
Lindsey Neville 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

November 07, 2018 07:00 ET (12:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024